(ABUS) Arbutus Biopharma - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 858m USD | Total Return: 35.1% in 12m
Avg Turnover: 4.02M
Qual. Beats: 1
Rev. Trend: 23.2%
Qual. Beats: 1
Warnings
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Choppy
Tailwinds
Pead
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical firm focused on developing a functional cure for chronic Hepatitis B virus (HBV). Its primary pipeline includes Imdusiran, an RNAi therapeutic designed to suppress viral antigens, and AB-101, an oral PD-L1 inhibitor aimed at restoring immune response. The company leverages a strategic licensing agreement with Alnylam Pharmaceuticals for Lipid Nanoparticle (LNP) delivery technology.
Operating within the biotechnology sector, Arbutus utilizes a high-risk, high-reward business model characterized by heavy research and development spending and a reliance on intellectual property protection and clinical trial milestones. The HBV market remains a significant focus for drug developers due to the high global prevalence of the disease and the limitations of current lifelong suppressive therapies.
Investors can evaluate the company’s long-term valuation and clinical data points further on ValueRay.
- Imdusiran Phase 2a clinical data outcomes determine long-term HBV functional cure potential
- Patent litigation settlements or royalties from COVID-19 vaccine LNP technology use
- AB-101 Phase 1 trial results impact expansion of oral immunotherapy pipeline
- Cash runway sustainability depends on strategic partnerships and licensing revenue milestones
- FDA regulatory milestones for chronic Hepatitis B treatment protocols drive valuation shifts
| Net Income: 160.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.12 > 0.02 and ΔFCF/TA 38.06 > 1.0 |
| NWC/Revenue: 142.0% < 20% (prev 1.52k%; Δ -1.38k% < -1%) |
| CFO/TA -0.12 > 3% & CFO -34.4m > Net Income 160.7m |
| Net Debt (-94.6m) to EBITDA (156.3m): -0.61 < 3 |
| Current Ratio: 54.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.2m) vs 12m ago 2.36% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 97.14% > 50% (prev 5.47%; Δ 91.67% > 0%) |
| Interest Coverage Ratio: 1.82k > 6 (EBITDA TTM 156.3m / Interest Expense TTM 86.0k) |
| A: 0.98 (Total Current Assets 277.0m - Total Current Liabilities 5.11m) / Total Assets 277.2m |
| B: -4.37 (Retained Earnings -1.21b / Total Assets 277.2m) |
| C: 0.79 (EBIT TTM 156.3m / Avg Total Assets 197.1m) |
| D: 10.94 (Book Value of Equity 185.9m / Total Liabilities 17.0m) |
| Altman-Z'' = 9.02 = AAA |
| DSRI: 0.04 (Receivables 1.31m/1.18m, Revenue 191.4m/6.40m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.63 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 29.90 (Revenue 191.4m / 6.40m) |
| TATA: 0.70 (NI 160.7m - CFO -34.4m) / TA 277.2m) |
| Beneish M = 18.00 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 4.35 with a total of 847,356 shares traded.
Over the past week, the price has changed by +2.59%,
over one month by -1.81%,
over three months by -0.91% and
over the past year by +35.09%.
Arbutus Biopharma has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy ABUS.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 5.2 | 18.4% |
P/E Forward = 10.2459
P/S = 4.4833
P/B = 3.3179
Revenue TTM = 191.4m USD
EBIT TTM = 156.3m USD
EBITDA TTM = 156.3m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 631k USD (from shortTermDebt, last quarter)
Debt = 631k USD (from shortLongTermDebtTotal, last quarter) (leases 631k already included)
Net Debt = -94.6m USD (calculated: Debt 631k - CCE 95.2m)
Enterprise Value = 763.7m USD (858.3m + Debt 631k - CCE 95.2m)
Interest Coverage Ratio = 1.82k (Ebit TTM 156.3m / Interest Expense TTM 86.0k)
EV/FCF = -22.23x (Enterprise Value 763.7m / FCF TTM -34.4m)
FCF Yield = -4.50% (FCF TTM -34.4m / Enterprise Value 763.7m)
FCF Margin = -17.95% (FCF TTM -34.4m / Revenue TTM 191.4m)
Net Margin = 83.95% (Net Income TTM 160.7m / Revenue TTM 191.4m)
Gross Margin = unknown ((Revenue TTM 191.4m - Cost of Revenue TTM 44.0k) / Revenue TTM)
Tobins Q-Ratio = 2.76 (Enterprise Value 763.7m / Total Assets 277.2m)
Interest Expense / Debt = 13.63% (Interest Expense 86.0k / Debt 631k)
Taxrate = 21.0% (US default 21%)
NOPAT = 123.5m (EBIT 156.3m * (1 - 21.00%))
Current Ratio = 54.26 (Total Current Assets 277.0m / Total Current Liabilities 5.11m)
Debt / Equity = 0.00 (Debt 631k / totalStockholderEquity, last quarter 260.2m)
Debt / EBITDA = -0.61 (Net Debt -94.6m / EBITDA 156.3m)
Debt / FCF = 2.75 (negative FCF - burning cash) (Net Debt -94.6m / FCF TTM -34.4m)
Total Stockholder Equity = 124.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 81.55% (Net Income 160.7m / Total Assets 277.2m)
RoE = 12.04% (Net Income TTM 160.7m / Total Stockholder Equity 1.33b)
RoCE = 11.71% (EBIT 156.3m / Capital Employed (Equity 1.33b + L.T.Debt 0.0))
RoIC = 69.58% (NOPAT 123.5m / Invested Capital 177.5m)
WACC = 9.04% (E(858.3m)/V(858.9m) * Re(9.04%) + D(631k)/V(858.9m) * Rd(13.63%) * (1-Tc(0.21)))
Discount Rate = 9.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 6.78%
[DCF] Fair Price = unknown (Cash Flow -34.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 23.21 | Revenue CAGR: 26.56% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.06 | Chg30d=+1.79% | Revisions=-20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.06 | Chg30d=+1.79% | Revisions=-20% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.23 | Chg30d=+1.09% | Revisions=+20% | GrowthEPS=+2.7% | GrowthRev=+1188.1%
EPS next Year (2027-12-31): EPS=-0.12 | Chg30d=N/A | Revisions=+20% | GrowthEPS=-112.0% | GrowthRev=-98.5%
[Analyst] Revisions Ratio: -20%